L-TRRiP model C and D - Evidencio
L-TRRiP model C and D

The L-TRRiP model predicts the chance on recurrence of VTE within two years of the first VTE. The model aims to guide healthcare professionals in treatment decisions.

Research authors: Timp JF, Braekkan SK, Lijfering WM, Van Hylckama Vlieg A, Hansen JB, Rosendaal FR
Version: 1.3
  • Public
  • Unspecified
  • {{ modelType }}
  • Details
  • Validate algorithm
  • Save input
  • Load input
Display
Units

{{section.title}}

Calculate the result

Set more parameters to perform the calculation

% chance of VTE recurrence within 2 years

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

Depending on the risk percentage, stopping anticoagulation may be considered. In case the bloodgroup and the Genetic Factor V Leiden mutation are known, the external validation study developed the following groups [1]:

  • Low Risk (<6%): stopping anticoagulants could be considered

  • Intermediate Risk (6%–14%): The decision to continue or stop anticoagulants is based on additional clinical judgment and patient preferences, balancing recurrence risk against bleeding risk. 

  • High Risk (>14%): Patients are typically recommended to continue anticoagulation due to the significant risk of recurrence. 

The external validation study states a management study, including the trade-off between anticoagulant risks and recurrence risks, should be done before implementing the L-TRRiP model into clinical practice. So that the clinical value of the model can be determined and patient groups (low, intermediate and high risk patients) can be defined [1].

If the bloodgroup or the Genetic Factor V Leiden mutation is unknown, the patient is considered high risk if the risk >10% and should continue anticoagulation treatment to prevent from recurrence [2]. Patients below the 10% risk are considered low risk and stopping anticoagulants should be considered. There is no intermediate risk group. This threshold based on International Society on Thrombosis and Haemostasis (ISTH) that states that patients with a yearly absolute risk of over 5% should receive anticoagulation treatment [3].

  • Low risk (<10%): stopping anticoagulants could be considered

  • High Risk (>10%): Patients are typically recommended to continue anticoagulation due to the significant risk of recurrence. 

Patients that experienced their first venous thromboembolism (VTE) are currently taking anticoagulants to prevent from recurrence of VTE, unless they are at high bleeding risk. The advantages and disadvantages of continuing or discontinuing anticoagulantion are a hard decision to be made by the healthcare professional. This decision is currently only based on patients having provoked or unprovoked VTE, with unprovoked VTE patient having to follow anticoagulation treatment. This results in many cases of over and under treatment [2].

The L-TRRiP model predicts the chance on recurrence of VTE within two years of the first VTE [2]. The model aims to guide healthcare professionals in treatment decisions.

Two versions of the model are created, model C and model D. Model C consists of two more variables: 'Bloodgroup' and 'Genetic Factor V Leiden mutation'.

An external validation study shows moderate discrimination results for model C and D [1]. This study states the need for a management study to assess the value of the model in clinical practice.

[1] Burggraaf-van Delft JLI, Wiggins KL, van Rein N, le Cessie S, Smith NL, Cannegieter SC. External validation of the Leiden Thrombosis Recurrence Risk Prediction models (L-TRRiP) for the prediction of recurrence after a first venous thrombosis in the Heart and Vascular Health study. Res Pract Thromb Haemost 2024;8:102610. https://doi.org/10.1016/j.rpth.2024.102610.

[2] Timp JF, Braekkan SK, Lijfering WM, van Hylckama Vlieg A, Hansen J-B, Rosendaal FR, et al. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Med 2019;16:e1002883. https://doi.org/10.1371/journal.pmed.1002883.

[3] Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting: Acceptable venous thromboembolism recurrence rates. J Thromb Haemost 2010;8:2313–5. https://doi.org/10.1111/j.1538-7836.2010.03991.x.

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This algorithm is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying algorithms Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Algorithm feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}

Evidencio Community Account Benefits

With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.

Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Terms & Conditions | Privacy Policy | Disclaimer | Contact | Refuse cookies |
Evidencio v3.35 © 2015 - 2025 Evidencio. All Rights Reserved